Health Care • Medical/Dental Instruments
$3.51 ▼ -0.37
(-9.54%)
MKT CAP: $1.9M • VOL: 60.2K
52W L $3 52W H $54
NXGL // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $11.4M | $8.7M | $4.1M |
| YoY Revenue Growth % | +31.5% | +112.5% | — |
| Gross Profit | $4.5M | $2.7M | — |
| Gross Margin % | 39.5% | 31.6% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$3.4M | -$3.6M | -$3.5M |
| Operating Margin % | -29.3% | -40.9% | -80.0% |
| Net Income (GAAP) | -$3.0M | -$3.3M | -$3.2M |
| EBITDA (Normalized) | -$3.3M | -$3.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$1.3M | -$3.9M | -$3.2M |
| Capital Expenditures (CapEx) | $68.0K | $443.0K | — |
| Free Cash Flow (FCF) | -$1.4M | -$4.3M | -$3.2M |
| FCF Margin % | -12.1% | -49.6% | -79.1% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | — | $1.8M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $4.5M | $5.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NXGL.